ClinicalTrials.gg

Program

bictegravir

Also written as “B/F/TAF”, “Bictegravir” and “BIC/LEN FDC”.

Its studies are mostly in Coinfection · Kidney Failure, Chronic · Mesothelioma, Malignant, led by 3 companies.

Furthest: phase 4, since Oct 23, 202325 company-led studies, 8 open or runningNext primary completion: Aug 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Gilead Sciences238 open or runningphase 4since Oct 23, 2023Oct 23, 2014Aug 2027phase 2 · NCT07645287
AGC Biologics10 open or runningphase 3since Mar 17, 2010Mar 17, 2010none ahead
Merck10 open or runningphase 1since Apr 8, 2026Apr 8, 2026none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 12 studies since Mar 17, 2010.

  1. Aug 13, 2018Phase 3 study in HIV-1 InfectionGilead Sciences · NCT03631732 · 496 enrolled · United States
  2. May 21, 2019Phase 1 study in HIV-1-infectionGilead Sciences · NCT03960645 · 62 enrolled · United States, Dominican Republic, Thailand
  3. Oct 28, 2019Phase 2 study in HIV-1-infectionGilead Sciences · NCT04143594 · 183 enrolled · United States, Dominican Republic, Puerto Rico
  4. Aug 5, 2022Phase 3 study in HIV-1-infectionGilead Sciences · NCT05502341 · 689 enrolled · United States, Argentina, Australia and more
  5. Oct 23, 2023Phase 4 study in HIV-1-infectionGilead Sciences · NCT06104306 · 33 enrolled · United States, Canada, France
  6. Mar 20, 2024Phase 3 study in HIV-1-infectionGilead Sciences · NCT06333808 · 577 enrolled · United States, Argentina, Australia and more
  7. Jul 29, 2024Phase 3 study in HIV-1-infectionGilead Sciences · NCT06532656 · 75 enrolled · United States, Argentina, Italy and more
  8. Oct 4, 2024Phase 3 study in HIV-1-infectionGilead Sciences · NCT06630286 · 609 enrolled · United States, Argentina, Australia and more
  9. Jun 27, 2025Phase 1 study in HIV-1-infectionGilead Sciences · NCT07055451 · 16 enrolled · United States, South Africa
  10. Apr 8, 2026Merck's first study: phase 1 study in HealthyNew to MerckMerck · NCT07532304 · 16 enrolled · United States
  11. Jun 8, 2026Phase 2 study in HIV-1-infectionGilead Sciences · NCT07645287 · 175 planned · United States, Australia, Canada and more
  12. Jul 13, 2026Phase 3 study in HIV-1-infectionGilead Sciences · NCT07708727 · 700 planned · United States, Canada, Germany and more
  13. Sep 29, 2026Primary completion moved from 2026-11 to 2030-07Date moved laterphase 3 · +44 months · NCT06532656
  14. Oct 26, 2026Phase 4 study in HIV-1 InfectionGilead Sciences · NCT07908446 · 400 planned

Ahead

  1. Aug 2027Primary completion: phase 2 study in HIV-1-infectionGilead Sciences · NCT07645287
  2. Mar 2028Primary completion: phase 1 study in HIV-1-infectionGilead Sciences · NCT07055451
  3. Jul 2028Primary completion: phase 4 study in HIV-1 InfectionGilead Sciences · NCT07908446
  4. Jul 2030Primary completion: phase 3 study in HIV-1-infectionGilead Sciences · NCT06532656

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“Human immunodeficiency virus type 1 integrase inhibitor; Human immunodeficiency virus type 1 integrase inhibitor”ChEMBL 37, by rule

Studies

All 25 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07908446HIV-1 Infection4Not yet recruitingGilead SciencesJul 2028400
NCT07708727HIV-1-infection · United States, Canada, Germany and more3RecruitingGilead SciencesOct 2030700
NCT07645287HIV-1-infection · United States, Australia, Canada and more2RecruitingGilead SciencesAug 2027175
NCT07532304Healthy · United States1CompletedMerckJul 23, 202616
NCT07055451HIV-1-infection · United States, South Africa1Active, not recruitingGilead SciencesMar 202816
NCT06630286HIV-1-infection · United States, Argentina, Australia and more3Active, not recruitingGilead SciencesApr 17, 2026609
NCT06532656HIV-1-infection · United States, Argentina, Italy and more3Active, not recruitingGilead SciencesJul 203075
NCT06333808HIV-1-infection · United States, Argentina, Australia and more3Active, not recruitingGilead SciencesOct 27, 2025577
NCT06104306HIV-1-infection · United States, Canada, France4CompletedGilead SciencesJan 29, 202533
NCT05502341HIV-1-infection · United States, Argentina, Australia and more3Active, not recruitingGilead SciencesSep 29, 2025689
NCT04143594HIV-1-infection · United States, Dominican Republic, Puerto Rico2CompletedGilead SciencesOct 5, 2021183
NCT03960645HIV-1-infection · United States, Dominican Republic, Thailand1CompletedGilead SciencesJul 21, 202262
NCT03631732HIV-1 Infection · United States3CompletedGilead SciencesAug 12, 2019496
NCT03547908HIV-1/HBV Co-Infection · United States, China, Dominican Republic and more3CompletedGilead SciencesFeb 25, 2022244
NCT03405935HIV-1 Infection · Belgium, France, Italy and more3CompletedGilead SciencesNov 20, 201886
NCT03110380HIV-1-infection · United States, Austria, Canada and more3CompletedGilead SciencesDec 4, 2018567
NCT02652624HIV-1 Infection · United States, Dominican Republic, Puerto Rico and more3CompletedGilead SciencesOct 9, 2017472
NCT02607956HIV-1 Infection · United States, Australia, Belgium and more3CompletedGilead SciencesMay 12, 2017657
NCT02607930HIV-1 Infection · United States, Belgium, Canada and more3CompletedGilead SciencesMay 9, 2017631
NCT02603120HIV-1 Infection · United States, Australia, Belgium and more3CompletedGilead SciencesMay 9, 2017567
NCT02600819Kidney Failure, Chronic · United States, Austria, France and more3CompletedGilead SciencesSep 29, 201755
NCT02397694HIV-1 Infection · United States2CompletedGilead SciencesNov 30, 201598
NCT02400307HIV · United States, New Zealand1CompletedGilead SciencesJul 6, 201519
NCT02275065HIV-1 Infection · United States1CompletedGilead SciencesJan 23, 201523
NCT01098266Mesothelioma, Malignant · United States, Belgium, Canada and more3CompletedAGC BiologicsApr 29, 2014400

How it is read

Names in the registry

  • “B/F/TAF”, 16 entries
  • “Bictegravir”, 3 entries
  • “BIC/LEN FDC”, 2 entries
  • “Bictegravir/Lenacapavir (BIC/LEN) FDC”, 2 entries
  • “Bictegravir/Lenacapavir”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.